

# Oviva Uk

## Prescribing Formulary For

### Oviva Tier 3 Weight

### Management Service

---

**Version:** 1

**Document Owner:** Oviva UK Medical Lead

**Authored by:** Dr Shaine Mehta, Oviva UK Medical Lead

**Date of last review:** February 2025

**Reviewed by:** Dr Waseem Majeed

**Contributors:** Yvonne Mckeown

**Date of next review:** February 2026, or in line with legislation changes

## Prescribing Formulary for Oviva Tier 3 Weight Management Service

**1. Purpose** The purpose of this document is to provide a clear and standardised prescribing policy for the use of Saxenda (liraglutide), Wegovy (semaglutide) and Mounjaro (tirzepatide) within Oviva's Tier 3 Weight Management Service, delivered remotely, and in alignment with the NHS prescribing formulary and NHS standard contract requirements. **\*Note Mounjaro is not yet prescribed within the service, pending further guidance from NHSE.**

**2. Scope** This policy and formulary applies to all healthcare professionals within Oviva authorised to prescribe, monitor, and review medications as part of the remotely delivered Tier 3 Weight Management Service.

### 3. Formulary Inclusions

Drug Name	Active Ingredient	Indication	Criteria for Use
Saxenda	Liraglutide	Weight management in adults with obesity	See Section 4.1.1
Wegovy	Semaglutide	Weight management in adults with obesity	See Section 4.1.2
Mounjaro*	Tirzepatide	Weight management in adults with obesity	See Section 4.1.3

### 4. Prescribing Standards

#### 4.1 Eligibility Criteria

**4.1.1 Saxenda (Liraglutide)** Saxenda will only be prescribed to patients who meet the following criteria:

- Body mass index (BMI)  $\geq 30$  kg/m<sup>2</sup>, or  $\geq 27$  kg/m<sup>2</sup> with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidaemia).
- Participation in Oviva's Tier 3 multidisciplinary weight management programme.
- Completion of baseline clinical assessments, including assessment of renal function and exclusion of contraindications.
- No contraindications to liraglutide.

**4.1.2 Wegovy (Semaglutide)** Wegovy will only be prescribed to patients who meet the following criteria:

- Body mass index (BMI)  $\geq 30$  kg/m<sup>2</sup>, or  $\geq 27$  kg/m<sup>2</sup> with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes).
- Participation in Oviva's Tier 3 multidisciplinary weight management programme.
- Completion of baseline clinical assessments (e.g., medical history, contraindications, and baseline bloods).
- No contraindications to semaglutide.

**4.1.3 Mounjaro (Tirzepatide)** Mounjaro will only be prescribed to patients who meet the following criteria, as outlined in NICE TA and in accordance with NHSE priority groups. Note Mounjaro is not yet prescribed within the service, pending further guidance from NHSE regarding priority groups. Currently, it may be recommended for patients with type 2 diabetes:

- Body mass index (BMI)  $\geq 35$  kg/m<sup>2</sup>, or  $\geq 32.5$  kg/m<sup>2</sup> for individuals from Black, Asian, and other minority ethnic groups, or  $\geq 30$  kg/m<sup>2</sup> in individuals with weight-related comorbidities (e.g., poorly controlled type 2 diabetes, hypertension).
- Participation in Oviva's Tier 3 multidisciplinary weight management programme.
- Completion of baseline clinical assessments, including glycaemic control markers for patients with type 2 diabetes.
- Demonstrated inability to achieve adequate weight loss through lifestyle interventions alone.

## **4.2 Initiation and Dose Escalation**

- Initiation must be by a qualified prescriber trained in Tier 3 weight management and pharmacotherapy.
- Gradual dose escalation as per the drug's Summary of Product Characteristics (SmPC) to reduce the risk of side effects.
- A shared decision-making process will be used to ensure patients are informed about potential benefits and risks.

## **4.3 Monitoring and Review**

- Regular remote follow-up appointments to assess efficacy and tolerability:
  - Weight and BMI monitoring.

- Review of side effects and adherence.
- Blood pressure and metabolic markers (as clinically indicated).
- Treatment discontinuation considered:
  - Weight loss of  $\geq 5\%$  is not achieved after 6 months.
  - Significant adverse effects are reported.

#### 4.4 Repeat Prescriptions

- Repeat prescriptions issued only after clinical review to confirm continued eligibility.
- Prescriptions will cover a maximum of 12 weeks to ensure regular monitoring.

#### 5. Exclusions and Contraindications

Drug Name	Contraindications	Cautions/Warnings
<b>Saxenda</b>	Hypersensitivity to liraglutide; MTC/MEN 2	Pancreatitis, renal impairment
<b>Wegovy</b>	Hypersensitivity to semaglutide; MTC/MEN 2	GI disease (including gallstones, pancreatitis, gastroparesis), pregnancy, breastfeeding
<b>Mounjaro</b>	Hypersensitivity to tirzepatide; MTC/MEN 2	Retinopathy, GI disease (including gallstones, pancreatitis, gastroparesis), pregnancy

**6. Adverse Event Reporting** All adverse reactions must be reported to the MHRA via the Yellow Card Scheme and documented within Oviva's clinical system.

#### 7. Responsibilities

- **Prescribers:** Ensure compliance with prescribing standards, maintain accurate records, and conduct regular reviews.
- **Patients:** Adhere to treatment plans, attend follow-ups, and report any side effects.
- **Quality & Governance Team:** Audit compliance, provide training, and address prescribing concerns.

#### 8. Training and Competency

- Mandatory competency assessment and training for prescribers on weight management pharmacotherapy.
- Refresher training provided annually or upon updates to clinical guidelines.

**9. Review and Update** This policy will be reviewed annually or sooner if required by updates to NICE guidance or the NHS standard contract.

#### **10. References**

- NICE Guidelines [NG245]: Obesity: Identification, assessment, and management.
- NICE Technology Appraisals for Semaglutide, Tirzepatide, and Liraglutide.
- SmPC for Wegovy, Mounjaro, and Saxenda.
- NHS Standard Contract 2023/24.